[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"omega-3-fatty-acids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:omega-3-fatty-acids":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,75,95,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100572719","omega-3-fatty-acids-and-subconcussive-head-impacts-100572719",false,"NCT06736925","Omega-3 Fatty Acids and Subconcussive Head Impacts","Mechanistic Investigation of Omega-3 Fatty Acids Pretreatment Effects on Subconcussive Brain Injury","Inclusion Criteria:\n\n* Between age 18-30\n* Current or former soccer player\n* At least 5 years of soccer heading experience\n* Have internet access\n* Willing to commit to avoid any sport activity that purposefully uses one's head to maneuver during the study period (American football, ice-hockey, rugby, wrestling, and soccer heading).\n\nExclusion Criteria:\n\n* Any head or neck injury within 6 months before the study\n* Implanted metal\u002Fmagnetic devices (e.g., orthodontic braces\n* Diagnosed autonomic or cardiovascular diseases (e.g., hypertension)\n* Consuming oily fish (2 servings or more\u002Fmonth: salmon, bluefin, swordfish, anchovies)\n* Allergy to fish or shellfish\n* Consuming omega-3 FA supplements including plant-based (e.g., flaxseed) in the past 3 months.\n* Pregnancy",true,"ALL","18 Years","30 Years",{"count":21,"type":22},208,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of the proposed double-blind, randomized placebo-controlled trial is to understand how supplementation with fish oil \\[docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)\\] promote brain health against soccer heading. The study involves taking DHA+EPA or placebo, questionnaires, blood draws, brain imaging, tests to evaluate heart function, and soccer headings.",[28,29],"Subconcussive Head Impact","Omega-3 Fatty Acids",[31,32,33,34],"Subconcussive brain injury","TBI","Soccer heading","Omega-3 fatty acids","RECRUITING","2026-04-28",{"date":38,"type":39},"2026-04-29","ACTUAL",{"date":41,"type":39},"2025-02-28",{"date":43,"type":22},"2029-05-31",{"name":45,"class":46},"Indiana University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100453181","phase-2-nmda-enhancement-combined-with-omega-3-for-early-dementia-100453181","NCT05181189","NMDA Enhancement Combined With Omega-3 for Early Dementia","NMDA Enhancement Combined With Omega-3 Fatty Acids for the Treatment of Early Dementia","Inclusion Criteria:\n\n* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment\n* MMSE between 10-26\n* CDR 1 or 0.5\n\nExclusion Criteria:\n\n* Hachinski Ischemic Score \\> 4\n* Substance abuse\u002Fdependence\n* Parkinson disease, epilepsy, dementia with psychotic features\n* Major depressive disorder\n* Major physical illnesses\n* memantine or special omega-3 fatty acids therapy within 3 months before enrollment\n* Severe visual or hearing impairment","50 Years","100 Years",{"count":58,"type":22},140,[60],"PHASE2","In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \\[1\\] DAOIB + omega-3; \\[2\\] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.",[63,64],"Omega 3 Fatty Acids","Dementia","NOT_YET_RECRUITING","2026-03-18",{"date":68,"type":39},"2026-03-20",{"date":70,"type":22},"2026-08",{"date":72,"type":22},"2028-03",{"name":74,"class":46},"Chang Gung Memorial Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100629902","can-people-achieve-a-target-omega-3-index-by-following-a-personalized-omega-3-dosing-regimen-100629902","NCT07480707","Can People Achieve a Target Omega-3 Index by Following a Personalized Omega-3 Dosing Regimen?","Effects of Using Personalized Dosage Recommendations of Parasol Omega-3 Fish Oil Based on Omega-3 Index Values: A Pilot Study","Inclusion Criteria:\n\n* Baseline omega-3 index less than 8%\n\nExclusion Criteria:\n\n* Currently taking a fish oil or other omega-3 supplement",{"count":83,"type":22},48,[25],"The goal of this project is to evaluate the efficacy of personalized dosage recommendations of Parasol Omega-3 Fish Oil on achieving an Omega-3 Index of \\>8% in individuals with a baseline Omega-3 Index \\\u003C8% over a 90-day period.",[29],"2026-03-14",{"date":66,"type":39},{"date":90,"type":22},"2026-05-01",{"date":92,"type":22},"2026-12-15",{"name":94,"class":46},"Fatty Acid Research Institute",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100598965","phase-2-omega-3d-omega-3-for-diet-driven-health-disparities-100598965","NCT07078344","Omega-3D: Omega-3 for Diet-Driven Health Disparities","Addressing Diet-Induced Health Disparities With Precision Nutrition and Omega-3 Fatty Acids","Inclusion Criteria:\n\n* Age ≥ 18 years\n* BMI ≥ 18.5 kg\u002Fm2\n* Self-identify as non-Hispanic African American or non-Hispanic European American\n* Ability and willingness to transport for regular clinic visits.\n* Ability and willingness to swallow study capsules.\n* Willingness to refrain from intentional weight loss\n* Willingness maintain usual physical activity levels and dietary intake throughout the trial.\n\nExclusion Criteria:\n\n* Age \\> 65 years\n* BMI ≥ 40 kg\u002Fm2\n* Currently pregnant or breastfeeding.\n* Currently receiving treatment for cancer (excluding adjuvant therapies).\n* Consumption of DHA\u002FEPA-rich fish 2 or more days a week (defined as \\>0.5 g DHA or EPA\u002Fserving)\n* Has a history of atrial fibrillation.\n* Has been diagnosed with a significant psychiatric condition that might compromise adherence to study protocols, including eating disorders, schizophrenia, bipolar (manic phase), severe personality disorders, severe major depressive, severe anxiety disorders, and substance use disorders.\n* Have an allergy to the study oils.\n* Have received other investigational agents within the past 6 months.\n* Currently on a weight reducing diet or has lost \\>5% body weight in the past 6 months.\n* Currently using GLP-1\n* Currently using prescribed anticoagulants or have a blood clotting problem or disease that causes excessive bleeding or been told by a physician that you have an increased risk of serious bleeding\n* Currently using oral steroids\n* Perceivably unable or unwilling to use acetaminophen in place of aspirin (including low dose regimen), NSAIDS, or other COX-2 inhibitors.\n* Perceivably unable or unwilling to refrain from using anti- inflammatory supplements (including n-3 supplements).\n* Perceivably unable or unwilling to refrain from using montelukast-type of allergy medications.\n* Run-in failure","64 Years",{"count":104,"type":22},200,[60],"The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 supplementation differ based on genetic variation in the FADS gene cluster (specifically rs174537)? Are changes in fatty acid ratios and inflammation markers greater among individuals of African ancestry compared to those of European ancestry? Researchers will compare omega-3 supplements to a placebo in a randomized, placebo-controlled crossover study to determine whether the Omega-3 supplementation is more effective in certain genetic and ancestry groups. Participants will take omega-3 supplements or a placebo daily for a defined period, then cross over to the other intervention. They will provide blood samples for analysis of fatty acid levels and inflammatory markers, complete questionnaires, and attend scheduled study visits.",[108,109,63],"Heart Health Markers","Cardiovascular Diseases","2025-12-12",{"date":112,"type":39},"2025-12-16",{"date":114,"type":39},"2025-07-31",{"date":116,"type":22},"2029-12-31",{"name":118,"class":46},"University of Arizona",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":119},"100602976","investigating-the-feasibility-of-krill-oil-intervention-to-improve-muscle-function-in-adults-with-long-term-conditions-100602976","NCT07130513","Investigating the Feasibility of Krill Oil Intervention to Improve Muscle Function in Adults With Long-term Conditions","The Effect of Krill Oil Supplementation on Muscle Function in Adults With High-risk Long-term Conditions: a Randomized Controlled Pilot Study.","KOMM","Inclusion Criteria:\n\n* Men and women aged ≥18 years who are in the high-risk long-term condition group (having one or more LTCs, including rheumatoid arthritis, gout, type 2 diabetes, coronary heart disease, and stroke \\[including transient ischemic attack, TIA\\]).\n\nExclusion Criteria:\n\n* Participants are diagnosed with and being treated for any type of cancer.\n* Presence of neurocognitive disorders or any health condition affecting memory (e.g., Alzheimer's disease, dementia).\n* Aortic stenosis, history of haemorrhagic stroke, or presence of aneurysms.\n* Current anticoagulant therapy.\n* Use of any muscle mass supplements or presence of physiological conditions such as pregnancy or breastfeeding.\n* History of allergy to fish or fish oil.\n* Regular consumption of more than one portion of oily fish per week, or use of fish oil or krill oil supplements.",{"count":129,"type":22},30,[25],"This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either:\n\n* Arm 1: Krill Oil group: 4 g\u002Fday of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or\n* Arm 2: Control group: 4 g\u002Fday of placebo (vegetable oil capsules).\n\nParticipants will be instructed to maintain their usual diet and physical activity patterns throughout the study.\n\nEligibility will be assessed using a health screening questionnaire, completed with the researcher's assistance, before obtaining informed consent. Habitual physical activity will be evaluated using the International Physical Activity Questionnaire (short form), and dietary intake will be assessed with the EPIC Food Frequency Questionnaire (FFQ) at both the beginning and end of the study. In addition, participants will record their fish consumption weekly using a dedicated logbook.\n\nMeasurements will be taken at baseline and after 12 weeks, including:\n\n* Blood samples to assess inflammatory and metabolic markers.\n* Anthropometry and body composition, including weight, height, fat mass, fat percentage, and muscle mass (via ultrasound).\n* Muscle strength, measured using handgrip strength and maximal voluntary contraction (each performed three times with rest between attempts).\n* Physical performance, assessed with a 4-meter walk test at normal speed Upon completing the study, participants will receive a £50 voucher in appreciation of their contribution.",[133,134,135,136,63],"Krill Oil","Muscle Function","Grip Strength","Long-Term Conditions","2025-10-01",{"date":139,"type":39},"2025-10-02",{"date":141,"type":39},"2025-08-18",{"date":143,"type":22},"2026-07-30",{"name":145,"class":46},"University of Glasgow"]